Join the Semaglutide group to help and get support from people like you.
Semaglutide News (Page 4)
Risk for CRC Reduced With GLP-1RAs for Drug-Naive Patients With T2D
MONDAY, Dec. 11, 2023 – For drug-naive patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1RAs) are associated with a reduced risk for colorectal cancer (CRC)...
American Academy of Ophthalmology, Nov. 3-5
The annual meeting of the American Academy of Ophthalmology was held from Nov. 3 to 5 in San Francisco and attracted participants from around the world, including ophthalmologists, optometrists,...
AHA: Semaglutide Cuts Risk for CVD Events in Patients Without Diabetes
MONDAY, Nov. 13, 2023 – Weekly subcutaneous semaglutide significantly cuts the incidence of cardiovascular death and nonfatal heart attacks and strokes in adults with preexisting cardiovascular...
AAO: Diabetic Retinopathy Usually No Worse With Semaglutide in T2D
THURSDAY, Nov. 9, 2023 – For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the...
FDA Investigating Hospitalizations Linked to Counterfeit Ozempic
WEDNESDAY, Nov 8, 2023 – The U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of the wildly popular weight-loss...
Wegovy, Ozempic Help Folks Lose Weight, But How?
TUESDAY, Oct. 10, 2023 – As many doctors and patients hail the advent of weight-loss drugs like Ozempic and Wegovy as the perfect fix for obesity, some experts are urging caution. The drugs are not...
GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
FRIDAY, Oct. 6, 2023 – Use of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss is associated with increased risks for pancreatitis, gastroparesis, and bowel obstruction compared...
Tirzepatide Bests Semaglutide for Patients With Type 2 Diabetes
THURSDAY, Oct. 5, 2023 – Tirzepatide is superior to semaglutide for both blood sugar control and weight loss among people with type 2 diabetes, according to research presented at the European...
Durable Reductions in HbA1c, Body Weight Seen With Semaglutide
WEDNESDAY, Oct. 4, 2023 – Use of once-weekly subcutaneous semaglutide is associated with sustained reductions in hemoglobin A1c (HbA1c) and body weight, according to a study presented at the annual...
Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...
Risk of Ileus Added to Ozempic Label
WEDNESDAY, Sept. 27, 2023 – Ozempic will now be labeled as having the potential to block intestines. The U.S. Food and Drug Administration recently made the label update for the drug made by Novo...
FDA Adds Warning to Ozempic Label About Risk for Blocked Intestines
WEDNESDAY, Sept. 27, 2023 – Ozempic, a type 2 diabetes drug that has increasingly been used to help with weight loss, will now be labeled as having the potential to block intestines. The U.S. Food...
Diabetes Drug Maker, Sues Over Compounded Versions of Mounjaro
WEDNESDAY, Sept. 20, 2023 – Another diabetes drug maker is taking legal action against businesses in several states, alleging that they’re “fraudulently claiming” that their compounded products are t...
ESC: Semaglutide Beneficial for HFpEF Patients With Obesity
TUESDAY, Aug. 29, 2023 – For patients with heart failure with preserved ejection fraction and obesity, semaglutide is associated with a larger reduction in symptoms and physical limitations,...
Semaglutide Can Cut Prevalence of Obesity, CVD in Eligible U.S. Adults
TUESDAY, Aug. 22, 2023 – Semaglutide treatment among eligible U.S. adults can reduce the prevalence of obesity and cardiovascular disease (CVD) events, according to a study published online Aug. 14...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Diabetes, Type 2